货号:A778486 同义名: M3814;Peposertib
M-3814, also known as MSC2490484A and nedisertib, is an orally available inhibitor of DNA-dependent protein kinase (DNA-PK), with potential antineoplastic and chemo/radiosensitizing activities.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | DNA-PK ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PI-103 |
++
DNA-PK, IC50: 23 nM |
99%+ | |||||||||||||||||
CC-115 |
+++
DNA-PK, IC50: 0.013 μM |
mTOR | 98+% | ||||||||||||||||
Samotolisib | ✔ | 99%+ | |||||||||||||||||
NU 7026 |
+
DNA-PK, IC50: 0.23 μM |
PI3K | 98+% | ||||||||||||||||
PIK-75 HCl |
++++
DNA-PK, IC50: 2 nM |
99%+ | |||||||||||||||||
PP121 |
+
DNA-PK, IC50: 60 nM |
VEGFR,PDGFR | 99%+ | ||||||||||||||||
KU-0060648 |
++++
DNA-PK, IC50: 5 nM |
99% | |||||||||||||||||
KU-57788 |
+++
DNA-PK, IC50: 14 nM |
99%+ | |||||||||||||||||
LTURM34 |
++
DNA-PK, IC50: 0.034 μM |
98%+ | |||||||||||||||||
SF2523 |
+++
DNA-PK, IC50: 9 nM |
99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | M-3814, also known as MSC2490484A and nedisertib, is an orally available inhibitor of DNA-dependent protein kinase (DNA-PK), with potential antineoplastic and chemo/radiosensitizing activities. Upon oral administration, the DNA-PK inhibitor MSC2490484A binds to and inhibits the activity of DNA-PK. This inhibits the ability of tumor cells to repair damaged DNA, which may lead to a reduction in cellular proliferation of cancer cells expressing DNA-PK. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02316197 | Advanced Solid Tumors ... 展开 >> Chronic Lymphocytic Leukemia 收起 << | Phase 1 | Completed | - | Germany ... 展开 >> Please contact the Merck KGaA Communication Center Darmstadt, Germany 收起 << |
NCT02516813 | Advanced Solid Tumors | Phase 1 | Recruiting | January 8, 2021 | United States, California ... 展开 >> Research site Recruiting Fresno, California, United States, 93720 United States, Florida Research site Recruiting Fort Lauderdale, Florida, United States, 33308 Research site Recruiting Miami, Florida, United States, 33136-1002 United States, Montana Research site Recruiting Billings, Montana, United States, 59101 United States, New York Research site Recruiting Bronx, New York, United States, 10461 United States, Pennsylvania Research site Recruiting Philadelphia, Pennsylvania, United States, 19107 United States, Texas Research site Not yet recruiting Houston, Texas, United States, 77030 United States, Washington Research site Completed Tacoma, Washington, United States, 98405 Belgium Research site Active, not recruiting Leuven, Belgium Denmark Research site Recruiting Copenhagen, Denmark, 2100 Research site Recruiting Herlev, Denmark Germany Research site Active, not recruiting Freiburg, Baden Wuerttemberg, Germany, 79106 Research site Recruiting Heidelberg, Baden Wuerttemberg, Germany Research site Recruiting Mannheim, Baden Wuerttemberg, Germany Research site Recruiting Tuebingen, Baden Wuerttemberg, Germany, 72076 Research site Recruiting Mainz, Rhineland-Palatinate, Germany, 55131 Research site Recruiting Dresden, Sachsen, Germany, 1307 Research site Recruiting Kiel, Schleswig-Holstein, Germany, 24105 Research site Recruiting Berlin, Germany, 12200 Netherlands Research site Recruiting Amsterdam, Netherlands, 1066 CX Research site 1 Active, not recruiting Amsterdam, Netherlands Norway Research site Active, not recruiting Oslo, Norway Sweden Research site Recruiting Solna, Sweden, 17176 收起 << |
NCT03724890 | Oncology Soli... 展开 >>d Tumors 收起 << | Phase 1 | Recruiting | October 9, 2020 | United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute, Inc Recruiting Tampa, Florida, United States, 33612 United States, Tennessee Tennessee Oncology- DDU Recruiting Nashville, Tennessee, United States, 37205 收起 << |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.08mL 0.42mL 0.21mL |
10.38mL 2.08mL 1.04mL |
20.75mL 4.15mL 2.08mL |
CAS号 | 1637542-33-6 |
分子式 | C24H21ClFN5O3 |
分子量 | 481.907 |
别名 | M3814;Peposertib;MSC2490484A |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Sealed in dry,2-8°C |
溶解度 | |
动物实验配方 |